~~<i id='5C253E7DE3'><strike id='5C253E7DE3'><tt id='5C253E7DE3'><pre id='5C253E7DE3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：fashion 2025-09-27 10:01:43 - browse：2

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

entertainment

Wikipedia

hotspot

explore

AdobeCHICAGO—Anext-generationCAR-Ttherapywasabletosubstantiallyshrinktumorsinpatientswithlivercancer

WSS

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Ultragenyx gene therapy for rare liver ailment succeeds in late

Pharma patents targeted by Biden in move to slash drug prices

See how much Covid

Kaiser's Risant Health gobbled up Geisinger. Who is next?

After sickle

Wikipedia

entertainment

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Teach medical students about patients with intellectual disabilities

Activists slam private health insurers over coverage restrictions

Chemotherapy shortages won’t get better under Biden’s latest plan

Malaria cases in Florida and Texas: Here’s what you need to know

See how much Covid

Anesthesiologist group: stop taking Ozempic before surgery

At ASCO, AstraZeneca reports strong data for breast cancer drug

Apple is now the first public company to be valued at $3 trillion

Woman returns to dialysis after doctors remove transplanted pig kidney

Wikipedia

The woman behind the Dana Farber

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Radiology is caught between AI's potential and concern for patients

Leukemia patients are helped by Syndax's new type of therapy

CMS should re

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

hotspot

hotspot

hotspot

explore